Compare MORN & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MORN | HALO |
|---|---|---|
| Founded | 1984 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 7.6B |
| IPO Year | 2005 | N/A |
| Metric | MORN | HALO |
|---|---|---|
| Price | $216.21 | $70.69 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $333.33 | $73.33 |
| AVG Volume (30 Days) | 359.2K | ★ 2.6M |
| Earning Date | 10-29-2025 | 11-03-2025 |
| Dividend Yield | ★ 0.85% | N/A |
| EPS Growth | 16.18 | ★ 56.68 |
| EPS | ★ 8.80 | 4.74 |
| Revenue | ★ $2,395,400,000.00 | $1,242,852,000.00 |
| Revenue This Year | $8.52 | $32.47 |
| Revenue Next Year | $7.45 | $24.31 |
| P/E Ratio | $24.47 | ★ $15.08 |
| Revenue Growth | 7.76 | ★ 31.19 |
| 52 Week Low | $202.89 | $46.26 |
| 52 Week High | $365.00 | $79.50 |
| Indicator | MORN | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 49.68 | 54.18 |
| Support Level | $205.97 | $68.09 |
| Resistance Level | $215.23 | $74.25 |
| Average True Range (ATR) | 4.04 | 2.25 |
| MACD | 1.07 | 0.28 |
| Stochastic Oscillator | 76.89 | 50.26 |
Morningstar Inc is a provider of independent investment research to financial advisers, asset managers, and investors. The company focuses its operations on two core sectors: data and research. It offers data on investments such as mutual funds, stocks, exchange-traded funds, closed-end funds, separate accounts, and variable annuities. Further, the company tracks real-time market data of equity, derivative, currency exchanges, and other investments. In its research operation, Morningstar offers analyst research on passive and active mutual funds, alternative funds, and college saving plans. Morningstar's majority of the revenue is generated in the United States of America.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.